Why is this ASX All Ords biotech share crashing 12% today?

This biotech is having a day to forget on Tuesday…

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is having a difficult day.

In afternoon trade, the biotechnology company's shares are down 12% to $1.48.

This makes the Paradigm share price one of the worst performers on the All Ordinaries index today.

A health professional wearing a stethoscope and scrubs shrugs with uncertainty.

Image source: Getty Images

Why is the Paradigm share price sinking?

Investors have been hitting the sell button on Tuesday after Paradigm announced the surprise exit of its CEO and managing director, Marco Polizzi.

According to the release, Mr Polizzi has stepped down from his role immediately and will cease employment with the company on 20 February.

Paradigm only announced the appointment of Polizzi at the end of May, with the experienced pharmaceutical industry executive commencing in the role on 1 July. At the time, the company hyped up his appointment, describing him as "a CEO with the skills to fully unlock the commercial value of the company."

No reason was given for the CEO's exit after just a few months with the company. Nor did Polizzi leave a parting comment, which is never a good look and could potentially be an indication of boardroom tensions.

What now?

The Paradigm board has acted quickly and appointed the company's founder and non-executive chairman Paul Rennie as its new leader. He said:

I am pleased to advise that the personal circumstances that originally required my stepping down from the Managing Director role in 2021, have now been successfully resolved. I look forward to working closely again with the Paradigm executive team and the Board in continuing our journey together.

Following today's decline, the Paradigm share price has now lost almost a third of its value over the last 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Happy healthcare workers in a lab.
Healthcare Shares

Mesoblast reports Ryoncil revenue surge and improved cash spend

Mesoblast reported a 44% jump in Ryoncil revenue and a substantial improvement in operating cash spend.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Down 44%: Will you regret not buying Pro Medicus shares?

The shares have fallen hard, but the business itself continues to grow at an impressive rate.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

CSL shares: Buy, hold, or sell?

The shares have recovered sharply, so I wanted to see whether the valuation still stacks up.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

Telix vs Clinuvel Pharmaceuticals: Which ASX healthcare share deserves your next $1,000 of investment capital?

We compare Telix and Clinuvel Pharmaceuticals on valuation, dividends, and momentum—which ASX healthcare stock looks more compelling now?

Read more »

Numerous Australian dollar notes laid out.
Healthcare Shares

I'd buy 6,462 shares of this ASX stock to aim for $200 a month of passive income

This business can provide very healthy dividends.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

UBS thinks Telix Pharmaceuticals shares will go how high?

Good news out of the US has led to a share price target upgrade.

Read more »

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »